Danish drugmaker Novo Nordisk must like what it has seen in its two-year-old alliance with gene-silencing specialist Dicerna Pharma – it has just agreed to acquire the biotech for $3.3 billion ...

Walmart has agreed to pay $10 million to settle a U.S. Federal Trade Commission civil lawsuit accusing the world's largest ...

Novo Nordisk said on Monday the European drugs regulator will allow a label update for its diabetes drug Ozempic to include a ...

Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a joint project to find new, gene-silencing drugs for liver-related cardiometabolic diseases.

Novo Nordisk (NVO-0.32%) has enjoyed tremendous success with semaglutide, the proprietary drug in Ozempic and Wegovy. However, competition is picking up with multiple next-generation drugs working ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually ...

Novo Nordisk has added another dimension to its artificial intelligence ambitions by signing up as a customer of Denmark’s first so-called “supercomputer.”. The supercomputer, named Gefion ...

As for improving access to obesity treatments, Novo has, in recent months, brought down the out-of-pocket price for Wegovy. In March, it began offering a one-month supply to self-paying customers ...

Novo Nordisk is locked in a patent infringement battle with Dr Reddy’s Laboratories and OneSource Specialty Pharma. SENSEX 82,408.17 + 1,046.30. NIFTY 25,112.40 + 319. ...

Novo Nordisk today announced that new hemophilia data will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Congress, June 21-25. Key data presentations ...

Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight ...

Shares of Novo Nordisk Inc. (NYSE: NVO) are trading lower Tuesday after a new study raised concerns about a potential link between GLP-1 weight loss drugs like Ozempic and an increased risk of ...